Puja Banka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Puja Banka has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
Andrew J. Powell
Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts, USA; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA
2 shared publications- Andrew J. Powell
Department of Cardiology, Boston Children’s Hospital, Boston, USA
2 shared publications - Ashwin Prakash
Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
2 shared publications James DiNardo
Department of Anesthesia, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts
2 shared publicationsJean Connor
Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts
2 shared publications- Kimberlee Gauvreau
Department of Cardiology, Boston Children’s Hospital and Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA
2 shared publications
Latest Publications
- 27 September 2023
- Published by Springer Nature
- p. 179-198
Abnormalities of Left Ventricular Inflow and Outflow
- 27 September 2023
- Published by Springer Nature
- p. 179-198
Abnormalities of Left Ventricular Inflow and Outflow
- Top Cited PapersOpen Access
- 1 May 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (2) , 144-158
Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor
Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2 decades of effort, an oral inhibitor of PCSK9 is not available. Macrocyclic peptides represent a novel approach to target proteins traditionally considered intractable to small-molecule drug design. Methods: Novel mRNA display screening technology was used to identify lead chemical matter, which was then optimized by applying structure-based drug design enabled by novel synthetic chemistry to identify macrocyclic peptide (MK-0616) with exquisite potency and selectivity for PCSK9. Following completion of nonclinical safety studies, MK-0616 was administered to healthy adult participants in a single rising-dose Phase 1 clinical trial designed to evaluate its safety, pharmacokinetics, and pharmacodynamics. In a multiple-dose trial in participants taking statins, MK-0616 was administered once daily for 14 days to characterize the safety, pharmacokinetics, and pharmacodynamics (change in low density lipoprotein cholesterol). Results: MK-0616 displayed high affinity ( K i = 5pM) for PCSK9 in vitro and sufficient safety and oral bioavailability preclinically to enable advancement into the clinic. In Phase 1 clinical studies in healthy adults, single oral doses of MK-0616 were associated with >93% geometric mean reduction (95% CI, 84–103) of free, unbound plasma PCSK9; in participants on statin therapy, multiple–oral-dose regimens provided a maximum 61% geometric mean reduction (95% CI, 43–85) in low density lipoprotein cholesterol from baseline after 14 days of once-daily dosing of 20 mg MK-0616. Conclusions: This work validates the use of mRNA display technology for identification of novel oral therapeutic agents, exemplified by the identification of an oral PCSK9 inhibitor, which has the potential to be a highly effective cholesterol lowering therapy for patients in need.
- 1 May 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (2) , 144-158
Top Cited PapersOpen AccessOrally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor
Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2 decades of effort, an oral inhibitor of PCSK9 is not available. Macrocyclic peptides represent a novel approach to target proteins traditionally considered intractable to small-molecule drug design. Methods: Novel mRNA display screening technology was used to identify lead chemical matter, which was then optimized by applying structure-based drug design enabled by novel synthetic chemistry to identify macrocyclic peptide (MK-0616) with exquisite potency and selectivity for PCSK9. Following completion of nonclinical safety studies, MK-0616 was administered to healthy adult participants in a single rising-dose Phase 1 clinical trial designed to evaluate its safety, pharmacokinetics, and pharmacodynamics. In a multiple-dose trial in participants taking statins, MK-0616 was administered once daily for 14 days to characterize the safety, pharmacokinetics, and pharmacodynamics (change in low density lipoprotein cholesterol). Results: MK-0616 displayed high affinity ( K i = 5pM) for PCSK9 in vitro and sufficient safety and oral bioavailability preclinically to enable advancement into the clinic. In Phase 1 clinical studies in healthy adults, single oral doses of MK-0616 were associated with >93% geometric mean reduction (95% CI, 84–103) of free, unbound plasma PCSK9; in participants on statin therapy, multiple–oral-dose regimens provided a maximum 61% geometric mean reduction (95% CI, 43–85) in low density lipoprotein cholesterol from baseline after 14 days of once-daily dosing of 20 mg MK-0616. Conclusions: This work validates the use of mRNA display technology for identification of novel oral therapeutic agents, exemplified by the identification of an oral PCSK9 inhibitor, which has the potential to be a highly effective cholesterol lowering therapy for patients in need.
- 1 May 2019
- Published by Elsevier in The American Journal of Cardiology
- Vol. 123 (9) , 1546-1554
Normal Values for Left Ventricular Strain and Synchrony in Children Based on Speckle Tracking Echocardiography
- 1 May 2019
- Published by Elsevier in The American Journal of Cardiology
- Vol. 123 (9) , 1546-1554
Normal Values for Left Ventricular Strain and Synchrony in Children Based on Speckle Tracking Echocardiography
- 1 October 2015
- Published by Elsevier in The American Journal of Cardiology
- Vol. 116 (7) , 1139-1143
Determinants of Resource Utilization in a Tertiary Pediatric and Congenital Echocardiographic Laboratory
- 1 October 2015
- Published by Elsevier in The American Journal of Cardiology
- Vol. 116 (7) , 1139-1143
Determinants of Resource Utilization in a Tertiary Pediatric and Congenital Echocardiographic Laboratory
- 1 March 2015
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 99 (3) , 939-946
A Method to Account for Variation in Congenital Heart Surgery Charges
- 1 March 2015
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 99 (3) , 939-946
A Method to Account for Variation in Congenital Heart Surgery Charges
- Open Access
- 1 January 2015
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 17 (1) , 1-8
Cardiovascular magnetic resonance techniques and findings in children with myocarditis: a multicenter retrospective study
- 1 January 2015
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 17 (1) , 1-8
Open AccessCardiovascular magnetic resonance techniques and findings in children with myocarditis: a multicenter retrospective study
- Open Access
- 1 December 2014
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 16 (1) , 73
Cardiovascular magnetic resonance parameters associated with early transplant-free survival in children with small left hearts following conversion from a univentricular to biventricular circulation
- 1 December 2014
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 16 (1) , 73
Open AccessCardiovascular magnetic resonance parameters associated with early transplant-free survival in children with small left hearts following conversion from a univentricular to biventricular circulation